# OnCo record erdafitinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/erdafitinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "erdafitinib" ;
  schema:name "Erdafitinib"@en ;
  schema:description "The first targeted pill for bladder cancer, for the roughly 20% of tumours with FGFR3 alterations, used after immunotherapy."@en ;
  schema:url <https://onco.cc/drugs/erdafitinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Erdafitinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27077213> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Erdafitinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (pan-FGFR)" ;
  schema:alternateName "Balversa" ;
  onco:approval "US 2019: FGFR3/2-altered advanced urothelial cancer after platinum (accelerated)", "US 2024: FGFR3-altered advanced urothelial cancer after ≥1 systemic therapy incl. PD-1/PD-L1 (full)" ;
  onco:acceleratedApproval "US 2019-04-12: Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has: susceptible FGFR3 or FGFR2 genetic alterations, and progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA." ;
  onco:acceleratedApprovalConfirmed "US 2024-01-19: Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has: susceptible FGFR3 or FGFR2 genetic alterations, and progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA." ;
  onco:related <https://onco.cc/biomarkers/fgfr3-alteration/> ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/muscle-invasive-bladder-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/fgfr2/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:pathways <https://onco.cc/pathways/fgfr-signalling/> ;
  onco:terms <https://onco.cc/terms/fgfr3/>, <https://onco.cc/terms/ocular-toxicity/> ;
  onco:trials <https://onco.cc/trials/thor/>, <https://onco.cc/trials/nct05316155/>, <https://onco.cc/trials/nct02365597/>, <https://onco.cc/trials/nct03473743/> .